NCT07108998 is a Phase 2 clinical trial of Epcoritamab in CLL/SLL, sponsored by Zulfa Omer.

Who is sponsoring NCT07108998?

NCT07108998 is sponsored by Zulfa Omer.

What drugs are being tested in NCT07108998?

Interventions in NCT07108998: Epcoritamab.

What condition does NCT07108998 study?

NCT07108998 studies CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant, Chronic Lymphocytic Leukemia Variants.

Is NCT07108998 still recruiting?

NCT07108998 is currently recruiting now. Last updated 6 January 2026.

Last reviewed 2026-01-06 · How we verify

NCT07108998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Recruiting now Phase 2 Last updated 6 January 2026

What this trial tests

Phase 2 trial testing Epcoritamab in CLL/SLL in 22 participants. Currently enrolling.

Timeline

22 August 2025

Primary endpoint
1 July 2027

1 July 2029

Quick facts

Lead sponsor	Zulfa Omer
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	22 August 2025
Primary completion	1 July 2027
Estimated completion	1 July 2029
Sites	1 location across United States

Drugs / interventions tested

Epcoritamab (EPCORITAMAB) — full drug profile →

Conditions studied

CLL/SLL — all drugs for CLL/SLL →
CLL — all drugs for CLL →
SLL — all drugs for SLL →
Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →

Sponsor

Zulfa Omer

Who can join

18 and older, any sex, with CLL/SLL or CLL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advancing Immunotherapy in Chronic Lymphocytic Leukemia.
Bieliński K, Wysocka A, Tyrna D, Robak T, et al · · 2026 · PMID 42123307 · DOI 10.3390/ijms27093722

Verify or expand the search:

Other trials of Epcoritamab

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07097363 — Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) · Phase 2 · recruiting
NCT06796998 — Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · Phase 2 · recruiting

Other recruiting trials for CLL/SLL

Currently open trials in the same condition.

NCT06978088 — LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This · Phase 2 · recruiting
NCT06508684 — Current Status of BTKi Treatment for CLL/SLL in China · recruiting
NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
NCT05590702 — French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Set · active not recruiting
NCT04775745 — Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. · Phase 1 · recruiting

Other Zulfa Omer trials

Trials by the same sponsor.

NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting
NCT06978088 — LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07108998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zulfa Omer
Last refreshed: 6 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07108998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing